• Categories
  • Archives

Doctors Without Borders Calls Brazil’s Bluff on AIDS Patent

International medical aid agency Médecins Sans Frontières (Doctors Without Borders, MSF) criticized the Brazilian government for failing to “keep its pledge” to break antiretroviral drug patents to produce generic versions of the medicines.

Brazil in March threatened to break the patents on four antiretrovirals by April 4 if the drug manufacturers did not agree to allow the country to produce generic equivalents or buy them at discounted prices, but it has not done so, according to news agencies.


The Brazilian government asked U.S. drug companies Merck, Gilead and Abbott Laboratories to grant the government voluntary licensing to produce generic versions of four drugs produced by the companies and used in Brazil’s National STD/AIDS Program.


The drugs in question include Merck’s Efavirenz, Abbott’s Lopinavir and Ritonavir and Gilead’s Tenofovir.


Brazil’s national AIDS program, which is considered to be one of the most progressive in the world, already manufactures and distributes generic versions of antiretrovirals, providing them at no cost to all HIV-positive people in the country.


The program ignores all patents issued before 1997, when Brazil signed an intellectual property law in order to join the World Trade Organization.


The government over the past three years repeatedly has said it might break patent laws in order to negotiate price reductions with pharmaceutical companies.


“The lack of action on the part of Brazilian authorities is incomprehensible. On the international level, Brazil has publicly defended using the flexibilities included in the World Trade Organization’s TRIPS agreement.


“But when it comes time to transforming this bold posture into acts that benefit the Brazilian population, the government resembles a toothless tiger,” MSF said in a statement, which was signed by 107 other nongovernmental organizations.


A Ministry of Health spokesperson said that breaking a patent is a “delicate process” and the country does not want the pharmaceutical companies to stop supplying the drugs before Brazil can produce generic equivalents, according to the Associated Press.


Supplying the four brand-name antiretrovirals would cost Brazil US$ 169 million – or 67% of the government’s budget for imported AIDS medications – this year, according to health ministry figures.


The Henry J. Kaiser Family Foundation
www.kaisernetwork.org

Tags:

  • Show Comments (0)

Your email address will not be published. Required fields are marked *

comment *

  • name *

  • email *

  • website *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ads

You May Also Like

Brazil Promising More Sugar and Coffee But Less Rice and Peanuts

In its second harvest estimate for 2006, which was released on Tuesday, March 7, ...

Latest News: Brazil Settles on Rafale After French Offer US$ 2 Billion Discount

Brazilian president Luiz Inácio Lula da Silva has denied, his Justice minister also, but ...

The Egyptian Antiques of Brazil’s Masp Museum

The São Paulo Art Museum (Masp) has in its collection Egyptian archaeological items. The ...

Brazilian Exports Grow 15% and Imports 23%

Brazilian exports added up to US$ 2.38 billion in the first four working days ...

Brazilian Indians Get Land, But Can’t Use It

On March 29, the bounds of the À‘ande Ru Marangatu indigenous land, located in ...

Brazil Is Getting Old: 15 Million Are Over 60

The demographer and researcher at the Institute of Applied Economic Research (IPEA), Ana Amélia ...

Will Brazil’s Sarney Fall on His Sword?

The Senate chairman, José Sarney, is following in the tradition of his predecessors and ...

Brazil? Oh my! How Do I Miss You!

Saudades (an intense homesick feeling), the Portuguese word which I finally understood as I ...

Rapidinhas

Behavior All Naked Getting naked in Brazil has become a fashionable statement for men ...

Brazil Offers Job Training for Poor Women

Brazil’s First Social Consortium of Youth (Consórcio Social da Juventude), which will train and ...